WO2022157747 - PHARMACEUTICAL GLP PEPTIDE COMPOSITIONS AND METHODS OF PREPARATION THEREOF
National phase entry:
Publication Number
WO/2022/157747
Publication Date
28.07.2022
International Application No.
PCT/IB2022/050644
International Filing Date
25.01.2022
Title **
[English]
PHARMACEUTICAL GLP PEPTIDE COMPOSITIONS AND METHODS OF PREPARATION THEREOF
[French]
COMPOSITIONS PEPTIDIQUES PHARMACEUTIQUES ET LEURS PROCÉDÉS DE PRÉPARATION
Applicants **
MYLAN IRELAND LIMITED
Unit 35/36, Grange Parade
Baldoyle Industrial Estate
Dublin, 13, IE
Inventors
BANASIAK, Katarzyna
132 Leargan
Western Distributor Road
Knocknacarra
Galway, IE
SIVADAS, Neeraj
Apt 2, 16 Ballymoneen Road
Galway, IE
FITZGERALD, Michael, Paul
Ceol na Coille
Ballard, Barna
Galway, IE
DOWNES, Claire
14 Caireal Mor
Headford Road
Galway, H91 HY82, IE
CARR, Paul
Kilmore, Belleek
Ballina
Mayo, IE
Priority Data
63/141,230
25.01.2021
US
63/189,863
18.05.2021
US
63/226,020
27.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1664 | |
| EPO | Filing, Examination | 8154 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 6510 |
Total: 17557 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed herein is a stabilized peptide composition that includes a glucagon-like peptide and a stabilizer. The stabilizer may be a stabilizing peptide having the same amino acid sequence as the glucagon-like peptide except the stabilizing peptide has at least one sequence alteration that may be a truncation, a deletion, a substitution and/or an insertion. Also disclosed are methods for making the stabilized peptide composition and its use for treating patients in need thereof.[French]
L'invention concerne une composition peptidique stabilisée qui comprend un peptide de type glucagon et un stabilisant. Le stabilisant peut être un peptide de stabilisation présentant la même séquence d'acides aminés que le peptide de type glucagon, à l'exception du peptide de stabilisation, et présente au moins une altération de séquence qui peut être une troncature, une délétion, une substitution et/ou une insertion. L'invention concerne également des procédés de fabrication de la composition peptidique stabilisée et son utilisation pour traiter des patients en ayant besoin.